Latest news with #FAP
Yahoo
7 hours ago
- Business
- Yahoo
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ('Biodexa' or 'the Company'), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, to provide information and resources for patients, caregivers, and healthcare professionals. Serenta reflects Biodexa's commitment to supporting the FAP community and fostering collaboration with stakeholders. The new website offers details about the study's objectives, background on FAP, and ongoing updates as the program progresses. 'We are pleased to introduce Serenta as the identity for our planned pivotal study of eRapa in FAP,' said Gary Shangold, CMO at Biodexa. 'Our goal is to provide clear, accessible information and to engage with the FAP community as we advance this important work.' For more information, please visit About eRapa eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 20480 180 About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
Borneo Post
13-06-2025
- Business
- Borneo Post
Bank Negara, Recoda team up to improve financial reach in rural Sarawak
Mohd Safri (sixth right) presents a memento to Rantai, while others look on. MIRI (June 13): The Highland Development Agency (HDA) office recently hosted a courtesy visit from Bank Negara Malaysia (BNM) Regional Office Kuching, led by its Head Rantai Naga, in conjunction with the central bank's working visit to Miri. The visit reinforced BNM's strategic commitment to ensuring that all Malaysians – especially those in rural and remote areas – have access to financial services. This includes physical access via Financial Access Points (FAPs), bank agents (EBs), cash recycle machines (CRM), and conventional bank branches or digital platforms. According to the Regional Corridor Development Authority (Recoda), six 'mukims' (districts) in Sarawak still lack FAP coverage. This includes three in the Miri Division – Bario, Mulu, and Long Bedian. During the session, Recoda director (Project Management Division) Mohammad Safri Ibrahim provided a comprehensive briefing on the proposed road network in northern Sarawak. This includes Northern Coastal Highway (NCH), Sarawak-Sabah Link Road (SSLR) Phase 1 & Phase 2, Miri-Marudi-Mulu-Long Lama, Sarawak Border Road (Long Banga-Bario-Bakelalan), as well as plans to improve rural connectivity between Long Lama and Long Bedian. The Public Works Department (JKR) Sarawak, led by SSLR project manager John Wong, presented an update on the current progress of SSLR Phases 1 and 2 during the visit. 'The improved infrastructure is expected to further facilitate financial inclusion and spur socio-economic growth in highland communities,' said Recoda. The collaboration between stakeholders underlines the importance of integrated planning that supports not only infrastructure but also financial accessibility in underserved communities, it added. Bank Negara banking financial HDA infrastructure lead Recoda rural
NDTV
11-06-2025
- Health
- NDTV
Appendix Cancer Cases On The Rise In Millennials; Everything You Need To Know
Appendix cancer is a rare type of cancer that begins in the cells lining the appendix, a small pouch attached to the large intestine. Though traditionally considered uncommon and mostly seen in older adults, recent studies show that appendix cancer is increasingly being diagnosed in younger populations, especially millennials. This rise is believed to be linked to a combination of lifestyle changes, such as increasing obesity rates, dietary shifts, gut microbiome alterations, and more frequent use of diagnostic imaging like CT scans that detect tumours incidentally. Common causes of appendix cancer Several factors can contribute to the development of appendix cancer. Genetic predisposition is one of the key causes, especially in individuals with inherited syndromes such as Lynch syndrome or familial adenomatous polyposis (FAP). Chronic inflammation in the digestive tract due to conditions like Crohn's disease or untreated infections can also lead to cellular mutations in the appendix lining. Lifestyle factors such as smoking, obesity, and diets high in processed foods and low in fibre may further promote an environment conducive to tumour growth. In some cases, long-term use of acid-reducing medications and previous history of gastrointestinal cancers may also increase risk. 10 Common signs of appendix cancer Persistent pain in the lower right abdomen. Often mistaken for appendicitis, this is one of the earliest signs when a tumour starts growing inside the appendix. Tumour growth or fluid accumulation in the abdomen can cause noticeable bloating that doesn't resolve easily. Weight loss without changes in diet or exercise may indicate underlying malignancies like appendix cancer. As tumour grow, they can interfere with digestion, causing persistent nausea. Constipation or diarrhoea that lasts more than a few days could be linked to gastrointestinal disruption caused by tumour. Tumour growth can reduce the available space in the abdomen, causing early satiety. A physical mass may be felt in the lower abdomen if the tumour becomes large. Cancer-related anaemia or inflammation can cause low energy levels and persistent tiredness. Advanced cases may lead to fluid buildup in the abdomen, causing visible swelling. In women, appendix cancer may mimic ovarian tumour and present as unexplained pelvic issues. 10 Prevention tips for appendix cancer Being overweight increases inflammation and insulin resistance, both of which are associated with higher cancer risk. Whole foods like fruits, vegetables, and whole grains support gut health and may help prevent mutations in digestive tract cells. Diets high in preservatives and sugar can fuel chronic inflammation and encourage abnormal cell growth. Physical activity boosts immune function, supports digestion, and helps maintain a healthy weight, all important in cancer prevention. Excess alcohol can damage the digestive tract lining and raise overall cancer risk. Smoking introduces carcinogens into the body, increasing the risk of cellular mutations in organs like the appendix. Unaddressed gastrointestinal infections may lead to prolonged inflammation and higher cancer risk. If you have conditions like Crohn's disease or chronic gastritis, regular follow-ups can help detect early changes. Genetic testing and early screening may be necessary if there's a strong family history of gastrointestinal or related cancers. Early diagnosis improves outcomes, so see a doctor if you notice ongoing digestive issues, bloating, or unexplained abdominal pain. As awareness and technology improve, more cases are being caught early, but the exact cause behind this generational shift remains under investigation.
Yahoo
10-06-2025
- Business
- Yahoo
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBS NeurAxis's PENFS technology is the only FDA-cleared or approved treatment that is recommended in the guidelines for pediatrics, enabling momentum for large-scale insurance coverage for IB-Stim® CARMEL, Ind., June 10, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ('NeurAxis,' or the 'Company') (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been officially incorporated into newly released clinical practice guidelines issued by the leading pediatric academic society for the treatment of Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS). This inclusion represents a major catalyst for NeurAxis, unlocking the potential for large-scale insurance coverage for its flagship product, IB-Stim, and setting the stage for accelerated growth through evidence-based recommendations. 'We are thrilled that IB-Stim is now recognized as part of the standard of care for FAP in IBS,' said Brian Carrico, CEO of NeurAxis. 'This milestone offers new hope to patients and reinforces the strength of our short and long-term growth strategy. Alongside our recent FDA expanded clearances for IB-Stim and our transformative, soon-to-be-effective on January 1st, Category I CPT code, we are now well-positioned to drive substantial top-line growth and operational leverage.' He added, 'With the recent strengthening of our balance sheet and the expected rollout of more widespread insurance coverage, we are poised to accelerate our treatment option to the over 600,000 kids in the United States suffering from FAP. We estimate the addressable market for our product just in the US to be over 3 billion dollars. With these important achievements now completed, I expect that this achievement will lead to a significant expansion of insurance coverage and revenue generation.' Dr. Adrian Miranda, practicing pediatric gastroenterologist and Chief Medical Officer of NeurAxis, commented: 'Overall, consensus was reached by the committee on 25 therapies and PENFS with IB-Stim was 1 of 4 therapies that had the highest level of evidence and thus placed amongst the top in the treatment algorithm for FAP in IBS.' Dr. Miranda also added, 'IB-Stim is not available in Europe, so the treatment algorithm was formulated to establish a framework for 'shared decision making' amongst the clinician and family, as opposed to a strict top to bottom approach. This gives clinicians the option to use IB-Stim as a first-line therapy and speaks to the overall certainty of the efficacy and safety supporting our technology. We couldn't be more pleased with this result.' Developing practice guidelines for FAP in IBS in children of 4–18 years was a collaborative effort of the European and North American Societies for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN and NASPGHAN). The guidelines followed the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) approach, which is supported by the World Health Organization (WHO). The highest GRADE therapies suggested in the guidelines include PENFS, hypnotherapy, lactobacillus rhamnosus (probiotic), and soluble fiber. This rigorous, evidence-based approach that incorporates PENFS as an important treatment option for children elevates NeurAxis's profile within the healthcare industry and supports wider market adoption of IB-Stim. Abdominal pain in IBS affects millions globally, creating a multi-billion-dollar market opportunity with limited effective treatment options. IB-Stim is the only pediatric treatment option that the FDA has cleared for FAP in IBS and abdominal pain in functional dyspepsia (to include nausea symptoms) for patients 8-21 years old. IB-Stim delivers gentle electrical impulses to cranial nerve bundles in the ear, offering a safe, non-invasive alternative to drug therapies often used off-label and many of which are not suggested in the practice guidelines from NASPGHAN / ESPGHAN. For more information about NeurAxis, please visit About NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit Forward-Looking StatementsCertain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company's stock, public health issues or other events, the Company's compliance with applicable laws, the results of the Company's clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis's public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise. For more information, please visit For contraindications, precautions, warnings, and IFU, please see: Contacts: CompanyNeurAxis, Investor Relations Lytham PartnersBen Shamsian646-829-9701shamsian@
Time of India
10-06-2025
- Health
- Time of India
Appendix cancer cases quadrupled among millennials, finds new study: What are its early symptoms?
Here's a bit of unsettling health news that's been turning heads lately: appendix cancer, once super rare, is now showing up more often in millennials. Yep, you read that right. According to a new study from Vanderbilt University Medical Center, people born between 1985 and 1990 are seeing four times as many cases as before. Those born between 1980 and 1985? Their risk has tripled. Even though appendix cancer still isn't super common—it affects about one or two people per million each year—the fact that it's rising among younger adults is raising some serious red flags. And it's not happening in isolation. Other cancers like colorectal, breast, uterine, pancreatic, and kidney cancers are also on the rise in younger people. So, what's going on? Why is this happening? Well, the exact reason is still kind of a mystery, but researchers have a few theories. 1. Lifestyle and diet changes: Our lifestyles have changed a lot over the years. Think: more processed foods, less movement, more screen time, and rising obesity rates. All of that adds up. 2. Environmental toxins: We're exposed to more stuff than ever—microplastics in our water, chemicals in our cleaning products, even pesticides in our food. It's possible these environmental triggers are doing long-term damage. Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trading CFD dengan Teknologi dan Kecepatan Lebih Baik IC Markets Mendaftar Undo 3. Genetics: Some people are more at risk because of inherited conditions like Lynch syndrome or FAP (familial adenomatous polyposis), which can increase your chance of getting appendix and other types of cancer. Appendix cancer: Early symptoms The thing with appendix cancer is that it can fly totally under the radar. Most people don't even know they have it until they're on the operating table getting their appendix removed for what doctors thought was just a case of appendicitis. Surprise—it's cancer. Here's what to watch for: A dull pain or discomfort in your lower right abdomen (where your appendix lives) that just doesn't go away Bloating that sticks around or feels abnormal Unexplained weight loss Feeling full quickly when eating, or just a weird, off feeling in your gut Changes in bathroom habits—constipation, diarrhea, or both on and off None of these scream "appendix cancer," which is what makes it so tricky. They're vague, and honestly, super easy to blame on stress, junk food, or even just a rough week. But if something feels off and it sticks around, don't ignore it. Why early detection matters Younger adults often get hit with more aggressive forms of appendix cancer, but they also tend to be healthier overall, which means they're better candidates for intense treatments like CRS and HIPEC. That's a combo of surgery to remove tumors followed by heated chemo poured right into the abdomen. It's a serious treatment, but it can be incredibly effective—especially if the cancer is caught early. What can you do? While you can't control everything, you can make some lifestyle choices that may help lower your risk. Move your body: Exercise regularly. It doesn't have to be intense—just stay active. Eat real food: Stick to whole, unprocessed foods as much as possible. Cut back on junk and sugary drinks. Go to the doctor—even when you feel fine: Routine checkups can catch things early, before symptoms even show up. Listen to your gut (literally): If something feels weird—pain, bloating, changes in digestion—don't brush it off. Talk to a doctor. One step to a healthier you—join Times Health+ Yoga and feel the change
